Postmarket safety communications on drugs approved in Japan: A 25-year analysis.

Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

Original Publication: Malden, MA : WileyBlackwell Pub., 2008-

Drug Approval* ; Product Surveillance, Postmarketing*/statistics & numerical data ; Drug-Related Side Effects and Adverse Reactions*/epidemiology; Japan ; Humans ; Retrospective Studies ; United States Food and Drug Administration/standards ; Drug Labeling/standards ; United States ; Adverse Drug Reaction Reporting Systems/statistics & numerical data

Drug safety communications (DSCs) are essential tools for communicating important postmarket serious drug safety information to healthcare professionals and patients. Previous studies characterized DSCs issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA); however, knowledge about the activities of the Pharmaceuticals and Medical Devices Agency (PMDA)/the Ministry of Health, Labor and Welfare (MHLW) is limited. This study characterized DSCs by the PMDA/MHLW in comparison with previously reported DSCs by the FDA and the EMA. We retrospectively analyzed 37 DSCs of 41 adverse drug reactions (ADRs) for 33 drugs in Japan from 1997 to 2022. Most DSCs were related to non-oncology drugs (30/37, 81.1%), and the median (interquartile range) time from approval to DSC issuance was 19 (10-51) months. Notably, the regulatory review reports and the latest labels before DSC issuance did not describe 16/28 (57.1%) and 12/37 (32.4%) of the ADRs related to DSCs, respectively. Most DSCs resulted in label revisions (36/37, 97.3%) and seven drugs were eventually withdrawn. Some DSC characteristics are similar among the PMDA/MHLW, the FDA, and the EMA; however, the number, contents, and range of new safety issues addressed by DSCs differ among the three jurisdictions. Our study emphasized the importance of continuous efforts to gather postmarket drug safety information because substantial ADRs that led to DSCs were recognized after approval and were associated with critical label revisions and withdrawals. Future studies are required to address global challenges for regulatory harmonization of safety-related regulatory actions.
(© 2024 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

J Clin Pharm Ther. 2019 Oct;44(5):788-795. (PMID: 31282013)
Drug Saf. 2022 Feb;45(2):169-180. (PMID: 35113347)
Clin Pharmacol Ther. 2021 May;109(5):1265-1273. (PMID: 33048367)
JAMA Intern Med. 2019 Nov 1;179(11):1592. (PMID: 31479098)
Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):687-94. (PMID: 26554874)
Pharmaceut Med. 2019 Oct;33(5):395-406. (PMID: 31933233)
Clin Transl Sci. 2024 Apr;17(4):e13803. (PMID: 38651283)
Clin Pharmacol Ther. 2018 Aug;104(2):390-400. (PMID: 29266187)
Ther Adv Drug Saf. 2021 Dec 16;12:20420986211065215. (PMID: 34987750)
JAMA Netw Open. 2019 Sep 4;2(9):e1910626. (PMID: 31483473)
J Cardiol. 2013 Dec;62(6):366-73. (PMID: 23838557)
JAMA. 2017 May 09;317(18):1854-1863. (PMID: 28492899)
JAMA Intern Med. 2019 Nov 1;179(11):1590-1592. (PMID: 31479104)

JP21K18094 JSPS KAKENHI

Date Created: 20240423 Date Completed: 20240429 Latest Revision: 20240429

20240501

PMC11036129

10.1111/cts.13803

38651283